drugset / Trial / NCT05238961

Neuroinflammation in Asymptomatic Carotid Artery Disease - Imaging Substudy

NCT05238961

Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

This clinical imaging substudy will use the small molecule translocator protein (TSPO) ligand, Fludeoxyglucose(18F)-labeled DPA-714, to compare neuroinflammation in individuals with high or low grade asymptomatic carotid artery stenosis (aCAD) who are participating in the separate Neuroinflammation in Asymptomatic Carotid Artery Disease study lead by Dr. Ron Lazar (IRB-300007806). The positron emission tomography (PET) tracer \[18F\]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia/macrophages and provides a non-invasive measure of neuroinflammation.

Timeline

Start
2028-04-01
Primary completion
2028-04
Completion
2028-04

Drugs

EvaluationDrugModalityDoseRoute
Subject [18F]DPA-714 Diagnostic / imaging agent